1. (Twice Amended) A topical composition for mutual enhancement of transdermal permeation of at least a first and a second pharmaceutically acceptable components which are both pharmacologically active agents, the composition comprising

an emulsion of at least one discontinuous phase in a continuous phase, the or each discontinuous phase comprising a eutectic mixture of first and second pharmacologically active agents and the continuous phase comprising a pharmaceutically acceptable carrier, the eutectic mixture having a melting point below 40°C; and

at least one compatible emulsifying agent,

wherein when the first pharmacologically active agent is a local anesthetic, the second pharmacologically active agent is not a local anaesthetic, wherein when the second pharmacologically active agent is a local anesthetic, the first pharmacologically active agent is not a local anesthetic, and wherein the first and the second pharmacologically active agents are each a prophylactic or a therapeutic agent.

9. (Amended) The topical composition according to Claim 1, in which said at least one discontinuous phase consists essentially of the eutectic mixture.

14. (Amended) The topical composition according to Claim 1, in which the pharmaceutically acceptable carrier is substantially hydrophilic, said carrier comprising substantially water as the continuous phase.

23. (Twice Amended) A method for mutual enhancement of dermal permeation of at least a first and a second pharmaceutically acceptable components which are both pharmacologically active agents, the method comprising

applying a topical composition for mutual enhancement of transdermal permeation of at least first and second pharmacologically active agents, the composition comprising

an emulsion of at least one discontinuous phase in a continuous phase, the or each discontinuous phase comprising a eutectic mixture of first and second pharmacologically active agents and the continuous phase comprising a pharmaceutically acceptable carrier, the eutectic mixture having a melting point below 40°C; and at least one compatible emulsifying agent,

wherein when the first pharmacologically active agent is a local anesthetic, the second pharmacologically agent is not a local anesthetic, wherein when the second pharmacologically active agent is a local anesthetic, the first pharmacologically active agent is not a local anesthetic, and wherein the first and the second pharmacologically active agents are each a prophylactic or a therapeutic agent,

to an accessible body surface of an animal.

31. (Amended) The topical composition according to Claim 9, in which said at least one discontinuous phase consists of the eutectic mixture.

34. (Amended) The method according to Claim 23, in which said at least one discontinuous phase consists essentially of the eutectic mixture.

35. (Amended) The method according to Claim 34, in which said at least one discontinuous phase consists of the eutectic mixture.

36. (Amended) The method according to Claim 23, in which the pharmaceutically acceptable carrier is substantially hydrophilic, said carrier containing substantially water as the continuous phase.